Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer Dodges Challenge to Its Board
Pfizer Dodges Challenge to Its Board in Fight With Starboard
Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter.
Pfizer Gets Breather From Starboard’s Ongoing Assault
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by its current leadership. But Bloomberg reports it has missed the deadline for nominating a director to the pharma’s board.
Pfizer avoids board nominations from Starboard as proxy fight rolls on: Bloomberg
Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the activist investor’s unfolding proxy fight. | Activist Investor Starboard Value stopped short of nominating any directors to Pfizer’s board ahead of a Jan.
Pfizer Jumps After Avoiding Proxy Fight With Activist Investor Starboard — For Now
Pfizer stock bounded off its 50-day line on Monday after avoiding a battle with activist investor Starboard Value — for now.
Starboard did not nominate Pfizer board members, Bloomberg says
Activist Starboard Value did not nominate any directors to Pfizer’s (PFE) board ahead of a January 25 deadline for the company’s annual meeting
Starboard refrains from nominating directors to Pfizer's board - Bloomberg
Investing.com -- Pfizer Inc. (NYSE: PFE) has temporarily avoided a standoff with activist investor Starboard Value LP. According to Bloomberg sources, Starboard did not put forward any nominations for Pfizer's board before the January 25 deadline for the pharmaceutical company's annual meeting in April.
Australian Associated Press
5d
Pfizer CEO did not say COVID vaccines are ‘quite dangerous’ in TV interview
Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...
5d
Pfizer’s Albert Bourla on Trump 2.0: ‘The status quo will collapse’
The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...
1d
What's Going On With Pfizer Stock Monday?
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...
21h
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
14d
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback